1240914-95-7

Upstream product

• 1123620-89-2 (1S,2S)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 170033-47-3 (R)-tert-butyl 2-methylpiperazine-1-carboxylate 
• 4209-02-3 1-(4-bromophenyl)-2-chloroethan-1-one 
• 6142-65-0 trans-(1S,2S)/(1R,2R)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 62566-68-1 (R)-2-(4-bromophenyl)oxirane 
• 875479-34-8 ethyl trans-2-(4-bromophenyl)cyclopropane-1-carboxylate 
• 1029431-48-8 (R)-1-(4-bromophenyl)-2-chloroethanol 
• 1332345-01-3 C₁₀H₉BrO₂*C₁₂H₁₃N 

Downstream Products

• 1240914-98-0 4-((1S, 2S)-2-((R)-4-cyclobutyl-2-methylpiperazine-1-carbonyl)cyclopropyl)benzonitrile 
• 1240914-03-7 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide 

Relevant academic research and scientific papers

Solid Forms Comprising A Cyclopropyl Amide Derivative

This disclosure relates to at least one solid form of 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide. This disclosure also relates to at least one pharmaceutical composition comprising at least one solid form described herein, methods of using the solid forms and pharmaceutical compositions comprised thereof, and processes of manufacturing the solid forms.

Cyclopropyl Amide Derivatives

Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.